Chemistry:Androstenetriol
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H30O3 |
| Molar mass | 306.446 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Androstenetriol (AET, androst-5-ene-3β,7β,17β-triol, β-androstenetriol, or βAET) is a steroid produced in the adrenal glands as a metabolite of DHEA.[1] It is believed to have similar effects as DHEA and androstenediol.[2] A study in rodents found that the compound was a weak androgen and estrogen, but did not attach to the androgen, estrogen, progesterone, or glucocorticoid receptors.[1] Synthetic analogs of AET known as HE3286[3] and NE3107 have been developed.[4]
References
- ↑ 1.0 1.1 Ahlem, Clarence N.; Auci, Dominick L.; Nicoletti, Ferdinando; Pieters, Raymond; Kennedy, Michael R.; Page, Theodore M.; Reading, Christopher L.; Enioutina, Elena Y. et al. (2011). "Pharmacology and immune modulating properties of 5-androstene-3β,7β,17β-triol, a DHEA metabolite in the human metabolome". The Journal of Steroid Biochemistry and Molecular Biology 126 (3): 87–94. doi:10.1016/j.jsbmb.2011.04.010. ISSN 0960-0760. PMID 21570467. https://www.sciencedirect.com/science/article/abs/pii/S0960076011001038.
- ↑ Dillon, Joseph S. (2005). "Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate and Related Steroids: Their Role in Inflammatory, Allergic and Immunological Disorders". Current Drug Targets - Inflammation & Allergy 4 (3): 377–385. doi:10.2174/1568010054022079. PMID 16101547.
- ↑ Reading, Christopher L.; Frincke, James M.; White, Steven K. (24 February 2012). "Molecular Targets for 17α-Ethynyl-5-Androstene-3β,7β,17β-Triol, an Anti-Inflammatory Agent Derived from the Human Metabolome" (in en). PLOS ONE 7 (2): e32147. doi:10.1371/journal.pone.0032147. ISSN 1932-6203. PMID 22384159. Bibcode: 2012PLoSO...732147R.
- ↑ Reading, Chris L; Ahlem, Clarence N; Parameswaran, Narayanan (December 2021). "Rationale for an anti-inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial". Alzheimer's & Dementia 17 (S9). doi:10.1002/alz.057438.
 |  |
